Do you routinely send Oncotype Dx on ER positive tumors with node positive disease?  

If so, how do you counsel patients who are node positive with low or intermediate risk scores? How do you interpret the existing data? NCCN and ASCO guidelines are conflicting. 



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice